Gavi (the Global Alliance for Vaccines and Immunization) has entered an advance purchase agreement with Bavarian Nordic to secure 500,000 doses of the modified vaccinia Ankara-Bavarian Nordic (MVA-BN) mpox vaccine.
The vaccines, marketed under names including JYNNEOS and IMVANEX, are intended for supply in African countries.
Scheduled for delivery in 2024, the vaccines are financed by Gavi’s First Response Fund, a new emergency funding mechanism designed to expedite vaccine procurement during health crises.
The MVA-BN vaccine, which received WHO prequalification on 13 September 2024, will be supplied pending a supply agreement with UNICEF, Gavi’s alliance partner responsible for distribution.
The APA follows the delivery of 250,000 doses of Bavarian Nordic vaccines to the Democratic Republic of the Congo (DRC), donated by various countries and Bavarian Nordic itself.
The allocation of these doses follows WHO’s Access and Allocation Mechanism guidelines, ensuring they reach those most in need.
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
The MVA-BN vaccine is the only non-replicating mpox vaccine approved in Canada, the EU, Singapore, Switzerland, the UK and the US.
Initially developed as a smallpox vaccine for immunocompromised individuals, it is now indicated for adults at risk for smallpox or mpox.
Bavarian Nordic recently made a filing with the European Medicines Agency seeking to extend the vaccine’s approval to adolescents aged 12 to 17.
The company is also evaluating the vaccine’s safety and efficacy in children aged two to 12, in collaboration with partners such as the Coalition for Epidemic Preparedness Innovations (CEPI).
Bavarian Nordic president and CEO Paul Chaplin stated: “We are pleased to sign this agreement and strengthen our commitment to support Gavi and other global health partners, who have demonstrated strong leadership in making life-saving vaccines available for the vulnerable populations in developing countries for decades.
“The doses secured through this agreement will significantly increase the availability of mpox vaccines for African countries, and we are pleased that Gavi has selected our MVA-BN vaccine, which has proven highly effective during the global mpox outbreak in 2022.”
Bavarian Nordic recently announced plans to prioritise the production of two million mpox vaccines by the end of 2024 to help fight the disease in Africa.
